DGAP-News: MediClin AG
/ Key word(s): Quarterly / Interim Statement
Offenburg, 2 May 2022 Group sales for the 1st quarter of 2022 significantly above the previous year's figure In the 1st quarter of 2022, the continuous improvement in occupancy rates in the rehabilitation clinics, which began in the second half of 2021, continued despite high incidences. "Although the increase in Group sales over the first quarter of 2021 must be regarded in the context of the extremely weak prior-year quarter, the sales development in the first months of the year under review is nevertheless positive", commented Tino Fritz, CFO of MEDICLIN, on the current business development and added: "But we have also felt a significant increase in costs". In the first quarter of 2022, Group sales of EUR 174.2 mill. were EUR 17.8 mill. or 11.4 % above the comparable prior-year quarter. On the costs side, the cost of raw materials and consumables used was EUR 5.3 mill. or 18.6 % above the prior-year value. At plus EUR 4.0 mill., energy costs and laboratory tests account for the major share in the increase in raw materials and consumables used. Staff costs rose only moderately by EUR 0.9 mill. or 0.8 %. "At present, we assume that the pandemic will not have a significantly negative impact on the occupancy in the next two quarters, but we must assume that the much higher material expenses compared to the previous year will have a negative impact on earnings", said Dr. Joachim Ramming, CEO of MEDICLIN. However, he is confident that the development of sales and earnings on the back of rising demand for medical, therapeutic and nursing care services will lead to an increase in sales and earnings in the Group, provided that the consequences and effects of Russia's invasion of Ukraine will have no massive and lasting negative effect on the German economy. The interim report as of 31 March 2022 is available from today under www.mediclin.de in German and English. / About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510) MEDICLIN includes 35 clinics, seven care facilities and eleven medical care centers. The Group has around 8,350 beds/care places and employs around 10,200 people. In a strong network, MEDICLIN offers the pa-tient integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDI-CLIN designs the care and support of people in need of care according to their individual needs and per-sonal needs. MEDICLIN ─ a company of the Asklepios Group.
02.05.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | MediClin AG |
Okenstraße 27 | |
77652 Offenburg | |
Germany | |
Phone: | +49 (0)781 488-326 |
Fax: | +49 (0)781 488-184 |
E-mail: | alexandra.muehr@mediclin.de |
Internet: | www.mediclin.de |
ISIN: | DE0006595101 |
WKN: | 659510 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1341131 |
End of News | DGAP News Service |
|
1341131 02.05.2022
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.